Acute Pancreatitis Associated with Pegylated Interferon and Ribavirin Treatment of Chronic Hepatitis C, Genotype 1b with High Viral Load by Ando, Kenji et al.
 
Case Rep Gastroenterol 2009;3:372–376 
DOI: 10.1159/000256557 
Published online: November 21, 2009  © 2009 S. Karger AG, Basel 
ISSN 1662–0631 
www.karger.com/crg 
 
 
Soo Ryang Kim, MD    Department of Gastroenterology, Kobe Asahi Hospital, 3-5-25 Bououji-cho, Nagata-ku 
Kobe 653-0801 (Japan) 
Tel. +81 78 612 5151, Fax +81 78 612 5152, E-Mail asahi-hp@arion.ocn.ne.jp 
 
372
   
Acute Pancreatitis Associated 
with Pegylated Interferon and 
Ribavirin Treatment of Chronic 
Hepatitis C, Genotype 1b with 
High Viral Load 
Kenji Andoa    Soo Ryang Kima    Susumu Imotoa    
Taisuke Nakajimaa    Keiji Mitaa    Katsumi Fukudaa    
Miyuki Taniguchia    Noriko Sasasea    Akira Muramatsub    
Toshiyuki Matsuokac    Masatoshi Kudod    
Yoshitake Hayashie 
aDepartment of Gastroenterology, Kobe Asahi Hospital, Kobe, bDivision of Liver 
Diseases, Meimai Central Hospital, Akashi, cDepartment of Radiology, Osaka City 
University Medical School, Osaka, dDepartment of Gastroenterology and 
Hepatology, Kinki University School of Medicine, Osakasayama, and eDivision of 
Molecular Medicine and Medical Genetics, International Center for Medical 
Research and Treatment, Kobe University Graduate School of Medicine, Kobe, 
Japan 
 
Key Words 
Acute pancreatitis · Pegylated interferon · Ribavirin · Chronic hepatitis C, high serum 
hepatitis C viral RNA · Genotype 1b · Tumor necrosis factor-α · Interleukin-6 · 
Drug-induced pancreatitis 
 
Abstract 
Acute pancreatitis, an uncommon side effect of pegylated interferon α (PEG-IFN α) and 
ribavirin (RBV) combination therapy, has rarely been reported in the English language 
literature. Here, acute pancreatitis associated with PEG-IFN plus RBV treatment is 
described in three patients with chronic hepatitis C, genotype 1b with high serum 
hepatitis C virus RNA levels. The patients had been started on weekly subcutaneous 
injections of PEG-IFN α (60, 80, and 90 μg) plus a daily oral dose of RBV (600 mg). The 
therapy was discontinued, however, because of the onset of acute pancreatitis (after 
15 weeks, 48 weeks, and 3 weeks respectively). The drug-induced pancreatitis was 
diagnosed on the basis of elevated levels of amylase and lipase and the absence of other 
identifiable causes. High tumor necrosis factor-α was found in one patient and high 
interleukin-6 in the other two. The immune system stimulated by PEG-IFN and RBV 
combination therapy might have caused the acute pancreatitis. Further study is needed  
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to clarify the mechanism of the onset of drug-induced pancreatitis by PEG-IFN and RBV 
combination therapy. 
 
Introduction 
Acute pancreatitis is an uncommon side effect of interferon α (IFN α) and ribavirin 
(RBV) combination therapy, and only few such cases have been reported in the English 
language literature [1]. It has been described in three cases of hepatitis C virus 
(HCV)-infected patients treated with pegylated interferon (PEG-IFN) plus RBV [2–4]. 
The pathogenesis of acute pancreatitis related to a stimulated immune system, however, 
has not been described. We present three cases of acute pancreatitis which may have been 
caused by the immune system stimulated by tumor necrosis factor alpha (TNF-α) and 
interleukin-6 (IL-6) associated with PEG-IFN plus RBV treatment of chronic hepatitis C 
(CHC), genotype 1b with high serum HCV RNA levels. 
Case 1 
A 67-year-old woman with CHC was admitted to Kobe Asahi Hospital in September 2007 for the 
treatment of abdominal pain.In June 2007, the patient with 44 kg body weight had been started on a 
weekly subcutaneous injection of 60 μg of PEG-IFN α-2b plus a daily oral dose of 600 mg RBV.Reverse 
transcription-polymerase chain reaction (RT-PCR) revealed 2,300 kIU/ml of HCV RNA and the 
hepatitis B surface antigen (HBsAg) and hepatitis B virus DNA were negative. The HCV core antigen by 
a new immunoradiometric assay was 5,550 fmol/l, and the genotype was 1b. Laboratory tests revealed 
the following: total protein (TP) 6.2 g/dl (normal 6.7–8.3), albumin (ALB) 3.8 g/dl (normal 3.8–5.3), 
aspartate aminotransferase (AST) 40 IU/l (normal 0–38), alanine aminotransferase (ALT) 29 IU/l 
(normal 0–19), platelets (PL) 13.9 × 10
4/μl (normal 14–34); liver biopsy revealed stage 1 fibrosis. The 
patient tolerated the therapy well until week 14, when she presented with severe epigastric pain 
radiating to her back, nausea, and vomiting. Laboratory tests at that time revealed the following: 
amylase (AMY) 178 IU/l (normal 38–136), lipase (LIPA) 521 IU/l (normal 23–300), AST 29 IU/l, ALT 
10 IU/l, alkaline phosphatase (ALP) 226 IU/l (normal 110–354), total billirubin (T-BIL) 0.5 mg/dl 
(normal 0.2–1.2), white blood cell (WBC) count 50 × 10
2/μl (normal 40–90), calcium (Ca)9.4 mg/dl 
(normal 8.7–10.1), total cholesterol (T-CHO) 140 mg/dl (normal 150–219), triglycerides (TG) 
153 mg/dl (normal 50–149), IgG4 20.1mg/dl (normal 4.8–105). TNF-α and IL-6 were 8.8 pg/ml 
(normal <5.0) and 3.4 pg/ml (normal <4.0), respectively. The patient had no history of pancreatitis, 
denied alcohol use, and was not taking any medications. Imaging studies such as ultrasound(US), 
computed tomography (CT) and magnetic resonance imaging (MRI) revealed no swelling of the 
pancreas or dilation of the pancreatic duct. The gallbladder appeared normal and no gallstones were 
noted. PEG-IFN α-2b and RBV were discontinued at 15 weeks after the start of therapy, and the patient 
was treated with ulinastatin 150,000 units/day for 4 weeks and camostat mesilate 600 mg/day orally for 
two weeks under the diagnosis of acute pancreatitis. The pancreatitis resolved and the patient was 
discharged in December 2007. 
Case 2 
A 60-year-old man was admitted to Kobe Asahi Hospital in October 2007 for the treatment of 
appetite loss and general fatigue. In November 2006 the patient with 58 kg body weight had been started 
on a weekly subcutaneous injection of 80 μg of PEG-IFN α-2b plus a daily oral dose of 600 mg RBV for 
the treatment of CHC. The RT-PCR revealed 5,100 kIU/ml of HCV RNA, and the genotype was 1b; 
HBsAg was negative. Laboratory tests revealed the following: TP 8.8 g/dl, ALB 3.5 g/dl, AST 53 IU/l, 
ALT 36 IU/l, PL 9.9 × 10
4/μl; liver biopsy was not done. 
The patient tolerated the therapy well and completed the 48-week course of PEG-IFN plus RBV in 
September 2007. Soon thereafter, the patient presented with appetite loss and general fatigue. 
Laboratory tests at admission revealed the following: AMY 316 IU/l, LIPA 1,373 IU/l, AST 42 IU/l, ALT 
10 IU/l, ALP 312 IU/l, T-BIL 0.5 mg/dl, WBC count 34 × 10
2/μl, Ca 7.7 mg/dl, T-CHO 135 mg/dl, TG  
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107 mg/dl, IgG4 5.5 mg/dl. TNF-α and IL-6 were ≤5 and 12.8 pg/ml, respectively. The patient had no 
history of pancreatitis, denied alcohol use, and was not taking any medications. US, CT and MRI 
revealed no swelling of the pancreas or dilation of the pancreatic duct. The gallbladder appeared normal 
and no gallstones were noted. The patient was treated with ulinastatin 150,000 units/day for 3 weeks 
under the diagnosis of acute pancreatitis. The pancreatitis resolved and the patient was discharged in 
November 2007. 
Case 3 
A 75-year-old woman, admitted to Kobe Asahi Hospital in April 2008 for the treatment of CHC, had 
44 kg body weight and was started on a weekly subcutaneous injection of 90 μg of PEG-IFN α-2a plus a 
daily oral dose of 600 mg RBV.TaqMan real-time PCR revealed 6.9 log kIU/ml of HCV RNA and the 
genotype was 1b; HBsAg and hepatitis B virus DNA were negative. Laboratory tests revealed the 
following: TP 7.1 g/dl, ALB 3.7 g/dl, AST 78 IU/l, ALT 112 IU/l, PL 7.7 × 10
4/μl; the liver biopsy 
revealed stage 3 fibrosis. The patient tolerated the therapy well until week 3, after which she complained 
of severe epigastric pain radiating to her back, nausea, and vomiting. Laboratory tests at that time 
revealed the following: AMY 155 IU/l, LIPA 1,153 IU/l, AST 43 IU/l, ALT 62 IU/l, ALP 213 IU/l, T-BIL 
0.3 mg/dl, WBC count 98 × 10
2/μl, Ca8.9 mg/dl, T-CHO 120 mg/dl, TG 161 mg/dl, IgG4 24.2 mg/dl. 
TNF-α and IL-6 were 1.8 and 7.9 pg/ml, respectively. The patient had no history of pancreatitis, denied 
alcohol use, and was not taking any medications. Imaging studies such as US, CT and MRI revealed no 
swelling of the pancreas or dilation of the pancreatic duct. The gallbladder appeared normal and no 
gallstones were noted. PEG-IFN α-2a and RBV were discontinued at 3 weeks after the start of therapy, 
and the patient was treated with ulinastatin 150,000 units/day for 4 weeks and camostat mesilate 
600 mg/day for 4 weeks under the diagnosis of acute pancreatitis. The pancreatitis resolved and the 
patient was discharged in June 2008 (table 1). 
Discussion 
Drug-induced pancreatitis is an uncommon side effect of IFN α, although several such 
cases have been published. Acute pancreatitis is described in a 9-year-old girl treated for 
14 months with IFN α, 3 million units daily, for chronic myelogenous leukemia [5]. Two 
other incidences of acute pancreatitis are described in adults treated with high doses (up 
to 10 million units daily) of IFN α for chronic myelogenous leukemia: one of the two 
patients developed recurrent pancreatitis after being rechallenged with a daily dose of 
10 million units of IFN α [6]. 
In the English language literature, only one case of acute pancreatitis has been reported 
in a 38-year-old man with HCV treated with only IFN α. The patient developed acute 
pancreatitis 2 h after receiving the first 5 million units injection of IFN α-2b. Although his 
symptoms resolved within 2 days, the patient developed recurrent pancreatitis 5 weeks 
after being rechallenged with 3 million units of IFN α-2b [7]. 
Onset of pancreatitis has not been reported among 1,010 patients treated with 
IFN α-2b plus RBV therapy in a large international multicenter registration trial [8]. 
Although only few cases of acute pancreatitis have been reported in patients treated with 
IFN α-2b and RBV combination therapy [1], the acute pancreatitis has been attributed to 
RBV, with the antiviral treatment being resumed with IFN alone. Nonetheless, such 
patients developed acute pancreatitis within hours of being rechallenged with IFN α-2b. 
Acute pancreatitis has been reported in 3 cases of HCV-infected patients treated with 
PEG-IFN plus RBV therapy [2–4]; however, its pathogenesis has not been described. 
In our cases, the drug-induced acute pancreatitis was diagnosed on the basis of the 
presence of symptoms such as epigastric pain, appetite loss, elevated amylase and lipase 
levels, and the absence of other identifiable causes of pancreatitis. The patients showed no 
evidence of gallstones, alcohol consumption, or other potential causes of pancreatitis such  
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as autoimmune pancreatitis with no elevation of IgG4. These findings meet the criteria 
for probable drug-induced pancreatitis. The onset of pancreatitis during PEG-IFN α plus 
RBV therapy and the resolution of the symptoms after discontinuing the treatment 
confirmed our diagnosis. Moreover, the consequent absence of recurrent pancreatitis also 
suggested that the medications were the most likely cause of acute pancreatitis. 
PEG-IFN and RBV combination therapy is a potential cause of drug-induced 
pancreatitis in patients with CHC, and IFN α can cause pancreatitis through several 
potential mechanisms. Treatment with IFN α can result in severe hypertriglyceridemia, a 
well-described cause of acute pancreatitis. In our cases, however, severe 
hypertriglyceridemia was not observed. Alternatively, PEG-IFN α may cause acute 
pancreatitis by stimulating the immune system, leading to autoimmune destruction of the 
pancreas. High TNF-α and IL-6 have been described as inducing and mediating acute 
pancreatitis, as have immunomodulatory cytokines [9, 10]. Indeed, high TNF-α was 
observed in case 1 and high IL-6 in cases 2 and 3. IFN α is known to precipitate or 
exacerbate other autoimmune disorders such as thyroid disease and diabetes. Based on 
the published literature, IFN α is more likely than RBV to cause acute pancreatitis, 
although RBV is known to exert immunomodulatory effects; also, RBV alone or 
synergistically with IFN α may stimulate the immune system to cause pancreatitis 
through an autoimmune mechanism. In our cases, however, high TNF-α (case 1) and 
high IL-6 (cases 2 and 3) may be markers of immune system stimulation by PEG-IFN and 
RBV or by acute pancreatitis itself.  
In conclusion, PEG-IFN α and RBV combination therapy is a potential cause of 
drug-induced pancreatitis in patients with CHC. In such individuals, pancreatitis is often 
severe enough to warrant hospitalization, although symptoms promptly resolve after 
discontinuation of antiviral therapy. Patients should be closely monitored during 
treatment and the medications should be discontinued when signs or symptoms of acute 
pancreatitis appear. Further studies are warranted to determine which of these two 
medications is associated with drug-induced pancreatitis, to investigate the mechanisms 
of pancreatic injury, and to evaluate the incidence of acute pancreatitis in HCV-infected 
patients treated with PEG-IFN and RBV. 
 
 
 
Table 1. Clinical profile of the three patients with acute pancreatitis 
Case Age 
(years) 
Gender IFN  IFN  dose  RBV  dose Duration  of 
treatment* 
AMY 
(IU/l) 
LIPA 
(IU/l) 
TNF-α 
(pg/ml) 
IL-6 
(pg/ml)
Case 1  67  female  PEG-IFN α-2b  60 μg/week  600 mg qd  15 weeks  178  0.521 8.8  03.4 
Case 2  60  male  PEG-IFN α-2b  80 μg/week  600 mg qd  48 weeks  316  1,373  .≤5 12.8 
Case 3  75  female  PEG-IFN α-2a  90 μg/week  600 mg qd  03 weeks  155  1,153  1.8  07.9 
* Duration of PEG-IFN α and RBV treatment before diagnosis of acute pancreatitis. Normal ranges: AMY 38–136 IU/l, 
LIPA 23–300 IU/l, TNF-α <5.0 pg/ml, IL-6 <4.0 pg/ml. qd = Daily. 
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